Skip to content
Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer

Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer

Get the podcast

COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O

The Audio Journal of Oncology

COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical Oncology 2016 congress in findings from the double-blind phase 3 European Network of Gynaecological Oncology Trial groups (ENGOT-OV16/NOVA) trial of the oral poly adenosine-diphosphate–ribose polymerase (PARP) 1/2 inhibitor, niraparib, compared with placebo in patients with platinum-sensitive recurrent ovarian cancer.

Mansoor Raza Mirza MD, Chief Oncologist at Copenhagen University Hospital and Medical Director of the Nordic Society of Gynaecologic Oncology discusses the findings with Peter Goodwin.

http://www.nejm.org/doi/full/10.1056/NEJMoa1611310#t=articleTop

Tags

ovarian cancer

Next in ESMO 2016

All 9 interviews

Interview 8 of 9

Cyclin-Dependent Kinase Inhibition Overcomes Endocrine Resistance in Advanced Breast Cancer

Cyclin-Dependent Kinase Inhibition Overcomes Endocrine Resistance in Advanced Breast Cancer

DESCRIPTION COPENHAGEN, Denmark—The efficacy of endocrine therapy in breast cancer was improved—in the MONALEESA-2 study—by the addition of the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib t

14 October 2016